RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis.
about
Accelerated partial breast irradiation: Past, present, and futureThe incidence of fat necrosis in balloon-based breast brachytherapyDevelopment and implementation of a remote audit tool for high dose rate (HDR) Ir-192 brachytherapy using optically stimulated luminescence dosimetry.Long-Term Cancer Outcomes From Study NRG Oncology/RTOG 9517: A Phase 2 Study of Accelerated Partial Breast Irradiation With Multicatheter Brachytherapy After Lumpectomy for Early-Stage Breast CancerLong-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma.Strut-adjusted volume implant (SAVI) brachytherapy-based accelerated partial breast irradiation (APBI) in African American women.Outcomes of Breast Cancer Patients Treated with Accelerated Partial Breast Irradiation Via Multicatheter Interstitial Brachytherapy: The Pooled Registry of Multicatheter Interstitial Sites (PROMIS) Experience.Dosimetric Comparison Between 3-Dimensional Conformal and Robotic SBRT Treatment Plans for Accelerated Partial Breast Radiotherapy.Cosmetic changes following surgery and accelerated partial breast irradiation using HDR interstitial brachytherapy : Evaluation by a multidisciplinary/multigender committee.
P2860
Q28069470-D83E88CF-8668-4D36-AC16-67BB54DCD27CQ35210311-3B5C051A-5E1E-4BE2-B93A-987410FDFD6AQ37288578-94BCFB2E-9CE9-4BD4-B9FE-FB7224399632Q37383075-B6DDA569-A595-47AD-860A-253CA910428CQ37579918-9BF02301-D489-4CA2-88A0-47B7936911DAQ40378218-28CF2A60-38AB-444B-957B-E8F5B363063EQ41008556-ADD71F77-53F8-48C1-9F46-0A852A730909Q46456504-3B37ED0B-4833-44E7-BBD3-8FF57666A5EDQ48102044-6534EE92-5661-4646-8499-ABEF05D53BEA
P2860
RTOG 95-17, a Phase II trial to evaluate brachytherapy as the sole method of radiation therapy for Stage I and II breast carcinoma--year-5 toxicity and cosmesis.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@en
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@nl
type
label
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@en
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@nl
prefLabel
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@en
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@nl
P2093
P2860
P921
P1433
P1476
RTOG 95-17, a Phase II trial t ...... -year-5 toxicity and cosmesis.
@en
P2093
Doug Arthur
Frank Vicini
John Bolton
Julia White
Kathryn Winter
Rachel Rabinovitch
Robert Kuske
Troy Scroggins
P2860
P356
10.1016/J.BRACHY.2013.08.002
P577
2013-09-14T00:00:00Z